Compare LQDA & AVPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | AVPT |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | United States |
| Employees | N/A | 3443 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 2020 | N/A |
| Metric | LQDA | AVPT |
|---|---|---|
| Price | $47.98 | $16.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 16 |
| Target Price | ★ $54.38 | $19.16 |
| AVG Volume (30 Days) | ★ 3.9M | 3.7M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $158,320,000.00 | N/A |
| Revenue This Year | $357.27 | $22.16 |
| Revenue Next Year | $1.34 | $20.53 |
| P/E Ratio | ★ $35.40 | $1,348.94 |
| Revenue Growth | ★ 1031.18 | N/A |
| 52 Week Low | $22.31 | $8.84 |
| 52 Week High | $93.61 | $17.52 |
| Indicator | LQDA | AVPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 61.63 |
| Support Level | $35.00 | $12.37 |
| Resistance Level | $63.46 | $17.52 |
| Average True Range (ATR) | 3.10 | 0.63 |
| MACD | 1.61 | -0.05 |
| Stochastic Oscillator | 77.29 | 69.54 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.